Close Menu

NanoString

Clearbridge subsidiary SAM Laboratory will be the exclusive provider of NanoString's Prosigna breast cancer prognostic gene signature assay in certain countries.

Validation results presented at the Association for Molecular Pathology meeting demonstrate that the test can be implemented clinically, replacing existing FISH and PCR assays.

The company believes it can overcome its challenges, and highlighted strong continued interest from pharma despite a disappointing end to its Merck deal.

The company saw total revenues of $27 million and product revenues of $16.9 million, as it had estimated in preliminary earnings report last month.

The index gained more than 3 percent, significantly outperforming the Nasdaq Biotechnology Index, but slightly underperforming the Dow and Nasdaq.

The partners will test samples from an NSABP biobank on Nanostring's platform and with standard IHC to look for newer biomarkers of cancer immune evasion.

In a note, Cowen analyst Doug Schenkel said the company has had trouble meeting its targets and suggested it pursue a strategic sale of its nCounter platform.

The firm estimated that its total revenue in the quarter was $25.9 million to $26.9 million with only $16.9 million coming from products and services.

The biggest losers following the release of the preliminary PAMA rates may be Quest and LabCorp, analysts said today. 

Pages

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.